Nitin Khanna was the owner of Saber, which is a company that helped states they contracted with manage their vehicle registration services along with other services the state offices for vehicle owner. Due to the success of Saber, it was purchased by EDS, which eventually became part of HP. The transaction was for $420 million. Most people would consider more social opportunities when they have just sold a company for $420 million. That’s not the case with Nitin Khanna though; he looked to develop another company as elaborated here.
That company he developed is MergerTech, and he operates it out of California. MergerTech is an investment bank that has found a niche to compete in. That niche is brokering the sale of companies with a value of less than $100 million. The reason he chose that value is because it is below the radar of largest investment banks giving him a chance to nurture his business in Portland, Oregon.
his business has allowed Nitin Khanna to focus on defining his niche. The first
part of the niche Nitin Khanna identified is businesses that are at risk of
going under and their investors want their money back. He sees these as
companies that can recover and thrive. Another type in the niche is companies
that are succeeding but have a need for cash from an investor. The final group
of small businesses he is focusing on is those that have gone through the
startup lifestyle and their owners would prefer to sell it and use that money
to create another startup and nurture that company. This new venture has been
detailed here https://www.tribuneindia.com/news/business/us-based-entreprenuer-invests-5million-in-mohali-start-up/397919.html
Khanna is playing the role of a matchmaker in the business world. As the CEO of
MergerTech, he is searching for companies that fall into each of the three
categories already discussed. He is then creating another list of contacts that
are investors that want to assist a startup with cash, or to take over a
company after they have matured from the startup phase. Nitin Khanna as a knack
for networking. Using that networking he is helping the overall economy on both
a micro and a macro level to grow through investment.
Marc Beer has years of experience in the commercial healthcare industry. He is a man of many titles in the same with his startups and affiliation with commercial health institutions. Before he co-founded the Renovia pharmaceuticals with Ramon Iglesias and Yolanda Lorie, Marc Beer has started a number of firms in the same business and led them to be the ultimate robust institution. Here are some of the institutions Marc Beer has worked with before Renovia.
Marc Beer is a graduate from the Miami University in Ohio with a bachelor’s of Science degree. As an alumnus of the university, Beer is a member of the Miami University business advisory team, among other titles. In commercial health, Marc Beer was the founding chair of the BOD of the compensation team of a recently acquired firm, Good Start Genetics. Marc beer holds a similar position in another firm, Minerva Neuroscience Inc., where he is also a member of the audit committee. Marc beer also held a number of positions in the sales and marketing team of the Abbott Laboratories. He also held a number of positions in Genzyme, the most recent on being the VP of the team that was responsible for launching new products to the market. The products that were launched addressed rare diseases populations globally. There are any more positions that Marc served in different institutions that are not covered here. These institutions include ViaCell, Erytech, and Aegerion Pharmaceuticals.
Renovia and the 42 million dollars fund.
Renovia Inc. was co-founded by Marc Beer to cater for disorders that affect the pelvic floor. Their first product was Leva devices, the was approved by the FDA. In the series B funding, the institution’s aim was to raise enough funds to help in the diagnostic and therapy of such disorders. Pelvic floor disorders like urinary incontinence have been proven by researchers to affect over a quarter million women worldwide. With the funds, Renovia will push on with the introduction of such new products and the advancement of their current Leva device. In the series, healthcare based institutions like Longwood, Perceptive Advisors in New York, and Ascension ventures in Missouri were leading in the series.
Marc Beer announced that the funds from the series would be used in the development and testing of a digital platform which will give Renovia’s clients with valuable information on new treatment paths, communicate to people information on pelvic floor disorders and finally lower the cost of the treatment of such disorders. The firm based in Boston acquired 32 million dollars from the like-minded institutions that participated in the series B round and sourced the remaining 10 million dollars from venture debts. The development of the therapeutic and diagnostic devices will improve the health and well being of millions of women once introduced in the market. Learn more: https://www.bizjournals.com/boston/news/2018/08/21/ex-aegerion-chief-beer-raises-42m-for-womens.html